Inhibikase Therapeutics, Inc. 8K

Inhibikase Therapeutics received FDA Orphan Drug Designation for its lead PAH candidate IKT-001, gaining potential regulatory and economic incentives for its ongoing development.

Inhibikase Therapeutics, Inc. announced that the U.S. Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of Pulmonary Arterial Hypertension (PAH), a rare, progressive and life‑threatening cardiopulmonary disease affecting an estimated 50,000 people in the United States. The designation, which applies to the active moiety imatinib rather than a specific formulation, provides potential development incentives including eligibility for tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and the possibility of seven years of U.S. market exclusivity upon approval. The company highlighted preclinical data presented at a recent American Thoracic Society conference showing improvements in pulmonary vascular and hemodynamic markers of PAH and a potentially lower risk of gastrointestinal toxicity relative to imatinib mesylate, and noted that its pivotal Phase 3 IMPROVE-PAH trial of IKT-001 is actively enrolling patients at approximately 180 global sites.

Filing Facts

CIK

1750149

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-313400

Alert Tier

6